Ca2+-activated IK K+ channel blockade radiosensitizes glioblastoma cells

Molecular Cancer Research

Volumn 13, Issue 9, 2015, Pages 1283-1295

  Stegen, Benjamin ^a   Butz, Lena ^a   Klumpp, Lukas ^a,b   Zips, Daniel ^a   Dittmann, Klaus ^a   Ruth, Peter ^a   Huber, Stephan M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; CALCIUM ION; DOUBLE STRANDED DNA; HISTONE H2AX; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; IONOMYCIN; MESSENGER RNA; PAXILLINE; POTASSIUM CHANNEL; CALCIUM; DACARBAZINE; H2AFX PROTEIN, HUMAN; HISTONE; POTASSIUM CHANNEL BLOCKING AGENT; PYRAZOLE DERIVATIVE; RADIOSENSITIZING AGENT; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM SIGNALING; CANCER GRADING; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SIZE; CANCER SURVIVAL; CELL ACTIVATION; CELL COUNT; CELL CYCLE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL MIGRATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; CLONOGENESIS; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMETRY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FETUS; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; IONIZING RADIATION; M PHASE CELL CYCLE CHECKPOINT; MITOSIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY; RADIOSENSITIZATION; REVERSAL POTENTIAL; S PHASE CELL CYCLE CHECKPOINT; STEADY STATE; SURFACE PROPERTY; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR INVASION; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; GLIOMA; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CALCIUM; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; GLIOMA; HISTONES; HUMANS; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICE; POTASSIUM CHANNEL BLOCKERS; PYRAZOLES; RADIATION-SENSITIZING AGENTS; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84942342279     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0075     Document Type: Article

References (49)

1. Stupp R, Van Den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005;5:198-206.
2. Evers P, Lee PP, De Marco J, Agazaryan N, Sayre JW, Selch M, et al. Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 2010;10:384.
3. Fioretti B, Castigli E, Calzuola I, Harper AA, Franciolini F, Catacuzzeno L. NPPB block of the intermediate-conductance Ca2+-activated K+ channel. Eur J Pharmacol 2004;497:1-6.
4. Fioretti B, Castigli E, Micheli MR, Bova R, Sciaccaluga M, Harper A, et al. Expression and modulation of the intermediate-conductance Ca2+-activated K+channel in glioblastoma GL-15 cells. Cell Physiol Biochem 2006;18:47-56.
5. Fioretti B, Catacuzzeno L, Sforna L, Aiello F, Pagani F, Ragozzino D, et al. Histamine hyperpolarizes human glioblastoma cells by activating the intermediate-conductance Ca2+-activated K+ channel. Am J Physiol Cell Physiol 2009;297:C102-10.
6. Cuddapah VA, Turner KL, Seifert S, Sontheimer H. Bradykinin-induced chemotaxis of human gliomas requires the activation of KCa3.1 and ClC-3. J Neurosci 2013;33:1427-40.
7. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci U S A 1997;94:11651-6.
8. Ruggieri P, Mangino G, Fioretti B, Catacuzzeno L, Puca R, Ponti D, et al. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS One 2012;7:e47825.
9. Catacuzzeno L, Fioretti B, Franciolini F. Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma. J Signal Transduct 2012;2012:421564.
10. Turner KL, Honasoge A, Robert SM, McFerrin MM, Sontheimer H. A proinvasive role for the Ca2+-activated K+ channel KCa3.1 in malignant glioma. Glia 2014;62:971-81.
11. Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, et al. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene 2009;28:1792-806.
12. Ouadid-Ahidouch H, Roudbaraki M, Delcourt P, Ahidouch A, Joury N, Prevarskaya N. Functional and molecular identification of intermediateconductance Ca2+-activated K+ channels in breast cancer cells: association with cell cycle progression. Am J Physiol Cell Physiol 2004;287:C125-34.
13. Jager H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 2004;65:630-8.
14. Wang J, Xu YQ, Liang YY, Gongora R, Warnock DG, Ma HP. An intermediateconductance Ca2+-activated K+ channelmediates B lymphoma cell cycle progression induced by serum. Pflugers Arch 2007;454:945-56.
15. Huber SM. Oncochannels. Cell Calcium 2013;53:241-55.
16. Huber SM, Butz L, Stegen B, Klumpp D, Braun N, Ruth P, et al. Ionizing radiation, ion transports, and radioresistance of cancer cells. Front Physiol 2013;4:212.
17. Huber SM, Butz L, Stegen B, Klumpp L, Klumpp D, Eckert F. Role of ion channels in ionizing radiation-induced cell death. Biochim Biophys Acta. 2014 Nov. 15. pii: S0005-2736 (14) 00390-3.
18. Khalid MH, Shibata S, Hiura T. Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg 1999;90:918-27.
19. Khalid MH, Tokunaga Y, Caputy AJ, Walters E. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg 2005;103:79-86.
20. Liu H, Li Y, Raisch KP. Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro. Anticancer Drugs 2010;21:841-9.
21. Steinle M, Palme D, Misovic M, Rudner J, Dittmann K, Lukowski R, et al. Ionizing radiation induces migration of glioblastoma cells by activating BK K+ channels. Radiother Oncol 2011;101:122-6.
22. Barry PH, Lynch JW. Liquid junction potentials and small cell effects in patch-clamp analysis. J Membr Biol 1991;121:101-17.
23. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol 2014;9:180.
24. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-4.
25. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6: pl1.
26. Huber SM, Tschop J, Braun GS, Nagel W, Horster MF. Bradykinin-stimulated Cl-secretion in T84 cells. Role of Ca2+-activated hSK4-like K+ channels. Pflugers Arch 1999;438:53-60.
27. Palme D, Misovic M, Schmid E, Klumpp D, Salih HR, Rudner J, et al. Kv3.4 potassium channel-mediated electrosignaling controls cell cycle and survival of irradiated leukemia cells. Pflugers Arch 2013;465:1209-21.
28. Huber SM, Misovic M, Mayer C, Rodemann HP, Dittmann K. EGFRmediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother Oncol 2012;103:373-9.
29. Heise N, Palme D, Misovic M, Koka S, Rudner J, Lang F, et al. Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+/calmodulindependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cell Physiol Biochem 2010;26:597-608.
30. Dittmann K, Mayer C, Rodemann HP, Huber SM. EGFR cooperates with glucose transporter SGLT1 to enable chromatin remodeling in response to ionizing radiation. Radiother Oncol 2013;107:247-51.
31. Motiani RK, Hyzinski-Garcia MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, et al. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Arch 2013;465:1249-60.
32. Wondergem R, Ecay TW, Mahieu F, Owsianik G, Nilius B. HGF/SF and menthol increase human glioblastoma cell calcium and migration. Biochem Biophys Res Commun 2008;372:210-5.
33. Bomben VC, Sontheimer H. Disruption of transient receptor potential canonical channel 1 causes incomplete cytokinesis and slows the growth of human malignant gliomas. Glia 2010;58:1145-56.
34. Catacuzzeno L, Aiello F, Fioretti B, Sforna L, Castigli E, Ruggieri P, et al. Serum-activated K and Cl currents underlay U87-MG glioblastoma cell migration. J Cell Physiol 2011;226:1926-33.
35. Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M, et al. CXCL12-induced glioblastoma cell migration requires intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol 2010;299:C175-84.
36. D'Alessandro G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M, et al. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 2013;4:e773.
37. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006;5:67.
38. Nakada M, Nambu E, Furuyama N, Yoshida Y, Takino T, Hayashi Y, et al. Integrin alpha3 is overexpressed in glioma stem-like cells and promotes invasion. Br J Cancer 2013;108:2516-24.
39. Turner KL, Sontheimer H. KCa3.1 modulates neuroblast migration along the rostral migratory stream (RMS) in vivo. Cereb Cortex 2014;24:2388-400.
40. Foller M, Bobbala D, Koka S, Boini KM, Mahmud H, Kasinathan RS, et al. Functional significance of the intermediate conductance Ca2+-activated K +channel for the short-term survival of injured erythrocytes. Pflugers Arch 2010;460:1029-44.
41. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM. Role of Ca2+activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-60.
42. Ataga KI, Orringer EP, Styles L, Vichinsky EP, Swerdlow P, Davis GA, et al. Dose-escalation study of ICA-17043 in patients with sickle cell disease. Pharmacotherapy 2006;26:1557-64.
43. Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008;111:3991-7.
44. Ataga KI, Stocker J. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia. Expert Opin Investig Drugs 2009;18:231-9.
45. Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011;153:92-104.
46. Maezawa I, Jenkins DP, Jin BE, Wulff H. Microglial KCa3.1 channels as a potential therapeutic target for Alzheimer's disease. Int J Alzheimers Dis 2012;2012:868972.
47. Lam J, Wulff H. The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression. Drug Dev Res 2011;72:573-84.
48. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
49. Cheng L, Huang Z, Zhou W, Wu Q, Donnola S, Liu JK, et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013;153:139-52.